Beam Therapeutics paired its third-quarter 2026 financial update with progress reports across its base-editing pipeline. The company said it had $1.0 billion in cash, cash equivalents and marketable securities at September 30, and expects that funding to support its operating plans into mid-2029.
The main near-term milestones are a possible U.S. marketing application for risto-cel, Beam’s sickle cell disease treatment, by year-end 2026, and continued clinical advances in programs for alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and phenylketonuria.
Key details
-
Risto-cel: Beam expects to submit a U.S. biologics license application for risto-cel as early as year-end 2026. The update did not provide further details on the treatment or the application.
-
BEAM-302 for alpha-1 antitrypsin deficiency (AATD): Updated Phase 1/2 results, with up to 18 months of follow-up after a single dose, showed durable increases in total and functional alpha-1 antitrypsin (AAT), alongside reductions in mutant Z-AAT and toxic Z-polymers. The company also reported lower neutrophil elastase activity and evidence that AAT production remained under normal physiological control.
- Beam says BEAM-302 is intended to address the underlying cause of AATD and could treat both its liver and lung manifestations.
-
Dosing and enrollment are continuing in a global pivotal cohort intended to support a potential U.S. accelerated-approval path. Beam expects to complete dosing in that cohort in the first half of 2027.
-
BEAM-301 for glycogen storage disease type Ia (GSDIa): Initial Phase 1/2 results presented in October showed clinical proof of concept for correcting the R83C mutation, a common cause of the disease. Enrollment in the 60-milligram dose cohort is underway.
-
BEAM-304 for phenylketonuria (PKU): Beam has nominated a third base editor in the program, bringing it to three editors aimed at distinct mutations. The company estimates the program could address up to 50% of PKU patients in the U.S., while research continues on other disease-causing mutations.
- The planned Phase 1/2 trial will initially test the R408W-targeting editor, assessing safety, tolerability and changes in blood phenylalanine levels. Beam expects dosing to begin in early 2027, with the goal of establishing clinical proof of concept and later evaluating editors for additional mutations within the same clinical program.
What changes for investors
The update sets out a series of clinical and regulatory milestones, but the programs remain investigational; the stated filing and trial timelines are company expectations, not approvals or completed milestones. Beam’s reported cash balance and estimated runway provide the funding backdrop for those plans, extending into mid-2029 by the company’s estimate.